BiotechTube

PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxel

Phase 3Terminated
0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

Conditions

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

Trial Timeline

Jan 6, 2025 → Dec 23, 2025

NCT ID
NCT06038539

About PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxel

PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxel is a phase 3 stage product being developed by Biocon for HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients. The current trial status is terminated. This product is registered under clinical trial identifier NCT06038539. Target conditions include HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients.

What happened to similar drugs?

3 of 20 similar drugs in HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients were approved

Approved (3) Terminated (2) Active (16)
✅Zoledronic acid + Standard TherapyNovartisApproved
✅Zoledronic Acid + PlaceboNovartisApproved
✅Taxane and Carboplatin + Short-term SintilimabInnovent BiologicsApproved
🔄E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3
🔄Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
🔄Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3
🔄SHR6390 + placeboJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical
17
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06038539Phase 3Terminated

Competing Products

20 competing products in HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

See all competitors
ProductCompanyStageHype Score
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
23
eFT508eFFECTOR TherapeuticsPhase 2
17
No drugDaiichi SankyoPre-clinical
30
ASP0113 + PlaceboAstellas PharmaPhase 2
35
Tivozanib Hydrochloride + paclitaxel + PlaceboAstellas PharmaPhase 2
27
EnzalutamideAstellas PharmaPhase 2
35
Cefiderocol + Standard of CareShionogiPhase 2
35
CefiderocolShionogiPre-clinical
26
Cefiderocol + Standard of CareShionogiPhase 2
35
Cefiderocol + Standard of CareShionogiPhase 2
35
E7389 (Eribulin Mesylate) + Vinorelbine injectionEisaiPhase 3
40
Durvalumab + EribulinEisaiPhase 1
29
Eribulin + Cyclophosphamide + DocetaxelEisaiPhase 2
35
eribulin mesylate + carboplatinEisaiPhase 2
31
Abemaciclib + BicalutamideEli LillyPhase 2
42
Camrelizumab + Apatinib + Nab-paclitaxel + Epirubicin + CyclophosphamideJiangsu Hengrui MedicinePhase 2
42
Camrelizumab Plus Chemotherapy + placebo+chemotherapyJiangsu Hengrui MedicinePhase 3
40
Fluzoparib; Apatinib + Fluzoparib + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 3
36
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
44
Camrelizumab + Nab-Paclitaxel + CarboplatinJiangsu Hengrui MedicinePhase 2/3
34